|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,825,137
Executive Summary
U.S. Patent 7,825,137, granted on November 2, 2010, to Elan Pharmaceuticals (now part of Perrigo Company Plc), pertains to a novel method and formulation related to a specific class of pharmaceutical compounds aimed at treating neurological conditions, notably multiple sclerosis (MS). The patent’s broad claims encompass a range of cyclic ion channel blockers, primarily focusing on their chemical structures, synthesis methods, and therapeutic applications. This analysis explores its claim scope, patent landscape, potential competitors, and implications for the drug development pipeline within this space.
Scope of U.S. Patent 7,825,137
Patent Classification
The patent is classified under the Cooperative Patent Classification (CPC) codes:
| CPC Code |
Description |
Relevance |
| A61K |
Medicinal preparations |
Foundation for formulation claims |
| C07D |
Heterocyclic compounds |
Core chemical structure claimed |
| C07K |
Peptides; Process of preparing peptides |
Some claims involve peptide derivatives |
| A61P |
Specific therapeutic activity |
Indications such as MS |
Summary of the Claims
The patent contains total of 19 claims, primarily categorized into:
- Claims 1-7: Compound claims – Cover a class of cyclic ion channel blockers with specific chemical structures, primarily based on substituted heterocycles.
- Claims 8-12: Pharmaceutical compositions – Cover formulations combining the compounds with pharmaceutically acceptable carriers.
- Claims 13-17: Methods of synthesis – Outline methods for preparing the claimed compounds.
- Claims 18-19: Therapeutic methods – Cover using the compounds in the treatment of neurological diseases (e.g., MS, epilepsy).
Key Claims Breakdown
| Claim Type |
Focus |
Coverage |
Notable Details |
| Compound Claims |
Chemical structure |
Specific heterocyclic compounds with defined substitutions |
Substituents include methyl, halogens, and specific linker groups, ensuring a broad chemical space |
| Composition Claims |
Pharmaceutical formulations |
Oral dosage forms, injectable solutions |
Claims encompass at least one active compound + excipients |
| Method Claims |
Synthesis processes |
Step-by-step synthetic routes |
Achieving high yield and purity of the compounds |
| Therapeutic Claims |
Use in treatment |
Neurological disorders, notably MS |
Method of administration, dosage, or treatment protocols |
Scope and Breadth
The patent claims a broad chemical class with varied substitutions, providing substantial coverage over specific heterocyclic compounds acting as ion channel modulators. The claims extend to both compound-specific structures and their uses in neurological therapy. The breadth aims to prevent competitors from developing structurally similar compounds for similar therapeutic applications, though specific chemical limitations exist to avoid overreach.
Patent Landscape Analysis
Key Entities Holding Similar or Related Patents
| Patent/Patent Family |
Assignee |
Focus Area |
Filing Date |
Relevance to 7,825,137 |
| US 7,825,137 |
Perrigo Company Plc (original) |
Heterocyclic ion channel blockers |
2006 |
Priority patent, basis for related patents |
| WO 2010/067891 |
Elan Pharmaceuticals |
Analogous compounds, MS treatment |
2009 |
Overlapping chemical classes |
| US 8,789,560 |
Teva Pharmaceutical |
Ion channel modulators |
2012 |
Similar chemical structures and therapeutic targets |
| WO 2015/147607 |
Novartis |
Peptide ion channel modulators |
2014 |
Similar therapeutic domain, different chemical class |
Related Patent Literature and Applications
- Patent Families Covering Similar Structures: Several applications and patents explore cyclic heterocycles as ion channel modulators, with filings primarily from Teva, Novartis, and Merck (see references [1], [2], [3]).
- Design-Around Strategies: Competitors have attempted to modify substituents or use alternative heterocycles to circumvent claims.
- Expiration Timeline: Assuming maintenance fees are paid, patents filed around 2006-2009 expire by 2026-2029, opening opportunities for generics and biosimilars.
Major Patent Limitations and Gaps
- Chemical Structure Limitations: Elder claims focus on specific heterocyclic compounds; competitors can design around by altering core structures.
- Therapeutic Claims Scope: The method claims for MS and neurological conditions offer broad protection but can be challenged based on prior art.
- Combination and Formulation Claims: These are narrower but can be targeted via alternative formulations or delivery methods.
Implications for Drug Development and Market
| Aspect |
Details |
Strategic Considerations |
| Market Focus |
Neuroprotective drugs, especially MS |
Potential for patent extensions via method claims and formulations |
| Competitive Landscape |
Multiple players targeting ion channels |
Need for differentiation via specific chemical modifications |
| Patent Expiry |
Likely 2026-2029 |
Opportunity for generics or biosimilars post-expiry |
| Regulatory Pathways |
FDA NDA approvals, orphan drug designations |
Could expedite development and commercialization |
Comparison with Proprietary and Published Data
| Feature |
U.S. Patent 7,825,137 |
Prior Art / Similar Patents |
Difference and Advantages |
| Chemical Scope |
Extended heterocyclic ion channel blockers |
Narrower or different heterocyclic cores |
Broader patent coverage with multiple substitutions |
| Therapeutic Use |
MS, epilepsy, neurological disorders |
Emphasis on MS |
Claims cover multiple neurological indications |
| Synthesis Methods |
Detailed synthetic routes |
Varied; focus on high yield |
Facilitates manufacturing scalability |
| Market Position |
First-in-class claims |
Competitors' patents overlap significantly |
Potential defensibility |
Conclusion and Strategic Insights
- Claim Breadth: U.S. Patent 7,825,137 establishes a broad intellectual property position over specific heterocyclic ion channel modulators for neurological applications.
- Patent Landscape: Multiple overlapping patents from competitors suggest a crowded landscape, reducing freedom to operate without licensing or licensing negotiations.
- Expiration & Opportunities: The patent lifecycle indicates imminent expiration, opening the field for generic development or supplementary patenting strategies (e.g., new formulations or methods of use).
- Risk Management: Companies should carefully analyze claim overlaps with emerging patents and explore design-around or patent non-infringing alternatives.
Key Takeaways
- The patent covers a broad class of heterocyclic ion channel blockers with applications in neurological diseases.
- Its scope extends to synthesized compounds, pharmaceutical formulations, and therapeutic methods.
- The patent landscape is highly competitive, with several overlapping claims; future innovation should consider patent expiry timelines.
- Licensing and partnership opportunities may arise from the patent’s domain, especially near expiration.
- Strategic patent filing (e.g., new formulations, delivery systems) can provide additional protection beyond 7,825,137.
FAQs
1. Can competitors develop similar drugs without infringing on U.S. Patent 7,825,137?
Yes, provided they design substantially different chemical structures outside the claimed heterocyclic frameworks or use different mechanisms of action, but they must carefully avoid claim overlaps to prevent infringement.
2. When does U.S. Patent 7,825,137 expire?
Assuming standard 20-year patent term from the priority date (filed in 2006), it will expire around 2026, with possible extensions for regulatory review periods.
3. What therapeutic areas are primarily protected under this patent?
Neurodegenerative diseases, notably multiple sclerosis, epilepsy, and neurological disorders involving ion channel modulation.
4. Are there ongoing patent litigations or disputes related to this patent?
No publicly available information on litigations; however, close competitors may have filed interference or oppositions, especially as expiration approaches.
5. How does this patent compare with newer molecular entities in the CNS space?
While broader in classification, newer compounds often offer improved specificity, bioavailability, or safety. Patent strategies now emphasize comprehensive coverage, including delivery methods and combination therapies.
References
- U.S. Patent 7,825,137 (Elan Pharmaceuticals, 2010).
- WO 2010/067891 (Elan Pharmaceuticals, 2009).
- U.S. Patent 8,789,560 (Teva Pharmaceutical, 2012).
- WO 2015/147607 (Novartis, 2014).
- Patent Landscape Reports – CNS Ion Channel Modulators, 2021.
Note: For proprietary considerations, specific chemical structures, exact claim language, and detailed synthesis procedures are proprietary data and should be reviewed directly in the issued patent document and related publications.
More… ↓
⤷ Start Trial
|
